FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)

CUSIP: 31189P102

Q2 2014 13F Holders as of 30 Jun 2014

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
122,342,805
Total 13F shares
9,853,337
Share change
+289,727
Total reported value
$62,410,000
Price per share
$6.31
Number of holders
21
Value change
+$1,716,802
Number of buys
12
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 31189P102?
CUSIP 31189P102 identifies FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
FMR LLC
13F
Company
2.5%
3,053,673
$29,743,000 31 Mar 2014
13F
Polaris Venture Management Co. V, L.L.C.
13F
Company
2%
2,473,186
$24,089,000 31 Mar 2014
13F
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
0.92%
1,121,180
$10,920,000 31 Mar 2014
13F
KINGDON CAPITAL MANAGEMENT, L.L.C.
13F
Company
0.91%
1,113,475
$10,533,000 31 Mar 2014
13F
ORBIMED ADVISORS LLC
13F
Company
0.57%
692,900
$6,749,000 31 Mar 2014
13F
Board of Trustees of The Leland Stanford Junior University
13F
Company
0.25%
303,538
$2,956,000 31 Mar 2014
13F
FARALLON CAPITAL MANAGEMENT LLC
13F
Company
0.22%
275,000
$2,679,000 31 Mar 2014
13F
PRINCIPAL FINANCIAL GROUP INC
13F
Company
0.17%
204,000
$1,987,000 31 Mar 2014
13F
VANGUARD GROUP INC
13F
Company
0.12%
148,606
$1,447,000 31 Mar 2014
13F
Bank of New York Mellon Corp
13F
Company
0.03%
38,400
$374,000 31 Mar 2014
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.02%
26,310
$256,000 31 Mar 2014
13F
UBS AG
13F
Company
0.02%
25,662
$250,000 31 Mar 2014
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.02%
23,728
$231,000 31 Mar 2014
13F
BlackRock Fund Advisors
13F
Company
0.02%
23,151
$225,000 31 Mar 2014
13F
DEUTSCHE BANK AG\
13F
Company
0.01%
16,905
$164,000 31 Mar 2014
13F
JANE STREET GROUP, LLC
13F
Company
0.01%
11,900
$116,000 31 Mar 2014
13F
WELLS FARGO & COMPANY/MN
13F
Company
0.01%
9,948
$97,000 31 Mar 2014
13F
PNC FINANCIAL SERVICES GROUP, INC.
13F
Company
0%
1,000
$10,000 31 Mar 2014
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
600
$6,000 31 Mar 2014
13F
MORGAN STANLEY
13F
Company
0%
349
$3,000 31 Mar 2014
13F
AMERICAN INTERNATIONAL GROUP, INC.
13F
Company
0%
99
$964 31 Mar 2014
13F

Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q2 2014

As of 30 Jun 2014, FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 9,853,337 shares. The largest 10 holders included FMR LLC, Polaris Venture Management Co. V, L.L.C., KINGDON CAPITAL MANAGEMENT, L.L.C., WELLINGTON MANAGEMENT CO LLP, ORBIMED ADVISORS LLC, Board of Trustees of The Leland Stanford Junior University, FARALLON CAPITAL MANAGEMENT LLC, PRINCIPAL FINANCIAL GROUP INC, VANGUARD GROUP INC, and DAFNA Capital Management LLC. This page lists 21 institutional shareholders reporting positions in this security for the Q2 2014 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2014 vs Q1 2014 Across Filers

Q1 2014 holders
21
Q2 2014 holders
21
Holder diff
0
Investor Q1 2014 Shares Q2 2014 Shares Share Diff Share Chg % Q1 2014 Value $ Q2 2014 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.